Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
New England Journal of Medicine · 18.07.2024 · 391 (3) · 213-223
DOI: 10.1056/nejmoa2314585 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 18.07.2024. Verfasst von Laurent Peyrin-Biroulet und 25 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, Fra…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Crohn Disease, Ustekinumab. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of Gastroenterology and Hepatology, McGill…
Förderung
- AbbVie
Zitieren
APA
Peyrin-Biroulet, L., Chapman, J. C., Colombel, J. F., Caprioli, F., D'Haens, G., Ferrante, M., Schreiber, S., Atreya, R., Danese, S., Lindsay, J. O., Bossuyt, P., Siegmund, B., Irving, P. M., Panaccione, R., Cao, Q., Neimark, E., Wallace, K., Anschutz, T., Kligys, K., …, & SEQUENCE Study Group (2024). Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. New England Journal of Medicine, 391(3), 213-223. https://doi.org/10.1056/nejmoa2314585
Vancouver
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. New England Journal of Medicine. 2024;391(3):213-223. doi:10.1056/nejmoa2314585
BibTeX
@article{PeyrinBiroulet2024,
author = {Peyrin-Biroulet, Laurent and Chapman, J Casey and Colombel, Jean-Frederic and Caprioli, Flavio and D'Haens, Geert and Ferrante, Marc and Schreiber, Stefan and Atreya, Raja and Danese, Silvio and Lindsay, James O and Bossuyt, Peter and Siegmund, Britta and Irving, Peter M and Panaccione, Remo and Cao, Qian and Neimark, Ezequiel and Wallace, Kori and Anschutz, Toni and Kligys, Kristina and Duan, W Rachel and Pivorunas, Valerie and Huang, Xiu and Berg, Sofie and Shu, Lei and Dubinsky, Marla and SEQUENCE Study Group, SEQUENCE Study Group},
title = {Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {3},
pages = {213--223},
doi = {10.1056/nejmoa2314585}
}
EUVIMED